Malmary M F, Kabbaj K, Labat C, Casse R, Oustrin J
Laboratoire de Biophysique, Biomathématiques et Informatique, Faculté des Sciences Pharmaceutiques, Université Paul Sabatier, Toulouse, France.
Chronobiol Int. 1991 Feb;8(1):25-34. doi: 10.3109/07420529109063916.
Cyclosporine A (CsA) nephrotoxicity was assessed in 120 male Wistar rats (350 +/- 50 g) entrained to a 12-h cycle (light-dark 12:12); plasma creatinine level and body weight were examined in controls and in rats that had been treated daily with oral CsA or vehicle alone (olive oil-ethanol 90:10) for 21 days; daily dosing (40 mg/kg) was at one of six equally spaced given times during the 24-h cycle. The variations observed in both indexes were shown to be circadian dosing stage dependent. Nephrotoxicity was present as early as the third day of treatment with CsA; plasma creatinine level was enhanced by about 50% in rats dosed around the time of the change from darkness to light: at 22 HALO, 146.7 +/- 4.5 mumol/L, against 92.0 +/- 2.8 mumol/L for controls (p less than 0.05); and at 2 HALO, 148.3 +/- 10.0 mumol/L, against 95.0 +/- 4.3 mumol/L for controls (p less than 0.05). Thereafter, a remission episode was observed between days D5-D9. The more drastic effects were seen on days D16 and D21, in animals dosed in the beginning of the dark span (14 HALO): 185 +/- 10 mumol/L for CsA and 98.0 +/- 5.3 mumol/L for controls (p less than 0.01) and, to a lesser extent, in rats treated at the early resting phase (2 HALO): 152.4 +/- 31 mumol/L for CsA and 95.0 +/- 4 mumol/L for controls (p less than 0.05). The normal increase in body weight during the 21-day period (about 14 +/- 8% in controls) was impeded in CsA-administered rats, especially those dosed at the beginning of the activity span (14 HALO) that even suffered weight reduction. Differences in percentages of survivors were noticed, depending on dosing stage. About 40% of the animals in every time CsA-treatment group died, except for those dosed at the end of the resting period (10 HALO), when all animals died. In surviving rats, the cessation of CsA dosing resulted in a reversible effect on the study variables.
在120只雄性Wistar大鼠(体重350±50克)中评估环孢素A(CsA)的肾毒性,这些大鼠被置于12小时的昼夜循环(光照-黑暗12:12)中;检测对照组以及每天口服CsA或单独给予赋形剂(橄榄油-乙醇90:10)处理21天的大鼠的血浆肌酐水平和体重;每日给药剂量为40毫克/千克,在24小时循环中的六个等间隔给药时间之一给药。观察到的两个指标的变化显示为昼夜给药阶段依赖性。早在用CsA治疗的第三天就出现了肾毒性;在从黑暗转变为光照时给药的大鼠中,血浆肌酐水平提高了约50%:在光照前22小时(HALO),为146.7±4.5微摩尔/升,而对照组为92.0±2.8微摩尔/升(p<0.05);在光照前2小时,为148.3±10.0微摩尔/升,而对照组为95.0±4.3微摩尔/升(p<0.05)。此后,在第5天至第9天观察到缓解期。在第16天和第21天,在黑暗期开始时(光照前14小时)给药的动物中观察到更明显的影响:CsA组为185±10微摩尔/升,对照组为98.0±5.3微摩尔/升(p<0.01),在休息早期(光照前2小时)给药的大鼠中影响较小:CsA组为152.4±31微摩尔/升,对照组为95.0±4微摩尔/升(p<0.05)。在21天期间对照组体重正常增加(约14±8%),而给予CsA的大鼠体重增加受阻,尤其是在活动期开始时(光照前14小时)给药的大鼠,甚至出现体重减轻。根据给药阶段,观察到存活百分比存在差异。除了在休息期结束时(光照前10小时)给药的动物全部死亡外,每次CsA治疗组中约40%的动物死亡。在存活的大鼠中,停止给予CsA导致研究变量出现可逆效应。